初诊急性髓系白血病近期药物获批:礼物还是特洛伊木马?
自2017年起,FDA批准glasdegib、venetoclax、ivosidenib、midostaurin、CPX-351和GO用于初诊AML,EMA批准midostaurin、CPX-351和GO。作者认为这些批准虽增加选择,但存在体能状态标准主观、缺乏与强化诱导随机对比、终点选择不当及注册研究人群代表性不足等问题。
要点
- venetoclax和glasdegib注册试验中体能状态标准主观,无PS 3-4患者,可能纳入适合强化诱导者。
- venetoclax联合HMA的完全缓解率与持续时间有限,缺乏与强化诱导的随机对比。
- ivosidenib和venetoclax批准仅基于缓解率,glasdegib批准仅基于生存而未含无事件生存。
核心结论
- 作者质疑venetoclax和glasdegib在缺乏与强化诱导随机对比情况下的批准。
- 作者对ivosidenib和venetoclax仅用缓解率、glasdegib仅用生存作为批准依据表示怀疑。
- 作者建议解决体能状态标准、随机化和终点选择等问题。
研究设计与样本
- 本文为针对FDA和EMA初诊AML药物获批的评论性文章,未报告系统检索范围。
主要发现
- venetoclax和glasdegib注册试验中无体能状态3-4患者。
- venetoclax联合 hypomethylating agent 试验的完全缓解率与持续时间有限。
- midostaurin和CPX-351的批准纳入人群未参与注册研究。
关键数值与推荐
- FDA批准药物包括glasdegib、venetoclax、ivosidenib、midostaurin、CPX-351和GO。
- EMA批准药物包括midostaurin、CPX-351和GO。
- venetoclax和glasdegib批准用于被认为不适合强化诱导者,但体能标准未明确定义。
临床怎么用
- 评估体能状态时应结合拟用疗法的潜在疗效,避免仅凭年龄≥75岁判断。
- 对venetoclax联合HMA的缓解率和持续时间应保持审慎,缺乏与强化诱导的随机对比数据。
- 关注ivosidenib和venetoclax批准仅基于缓解率、glasdegib仅基于生存的局限性。
局限性
- 本文为评论性文章,未提供原始研究数据或系统评价方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2017 the US Food and Drug Administration (FDA) has approved glasdegib, venetoclax, ivosidenib, midostaurin, CPX- 351, and gemtuzumab ozogamicin (GO) to treat persons with newly diagnosed acute myeloid leukemia. The European Medicines Agency (EMA) has done likewise for midostaurin, CPX-351, and GO. While increasing options for persons, particularly older ones, for whom current therapy is unsatisfactory, or simply not given, these approvals raise several concerns. Although the venetoclax and glasdegib approvals were for persons considered "unfit" for intensive induction, the criteria for fitness were not well defined (age ≥75 per se being insufficient) and are frequently subjective, making it likely that many subjects in the venetoclax and glasdegib registration trials were fit for intensive induction; for example, none had performance status 3-4. Fitness must be assessed together with the potential efficacy of a proposed therapy. We note the modest complete remission rates and durations in the venetoclax + hypomethylating agent trial. Although these formed the basis for FDA approval, it is unclear that better results might not have obtained with more intense induction, as several studies, with considerably longer-follow up, have suggested. Hence, we question the venetoclax (and glasdegib) approvals absent randomized comparisons with intense induction. Given the uncertain relation in older individuals between survival and complete remission (CR), much less responses less than CR, we are skeptical of the sole use of these responses in the ivosidenib and venetoclax approvals; we also question the use of survival, without event-free survival, in the glasdegib approval. Noting the midostaurin and CPX-351 approvals included populations not participating in the registration studies we suggest means to address this issue as well as those involving fitness, randomization, and endpoints.
引用
- Estey E, Karp JE, Emadi A, et al. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse? Leukemia. 2020. PMID: 31915366. doi:10.1038/s41375-019-0704-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。